ACAD — ACADIA Pharmaceuticals Inc. stock price, charts and financials

QT75ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
29.39
+0.18+0.62%
OverviewShort InterestFilings
ACADQT75ACADIA Pharmaceuticals Inc.·NASDAQ
29.39+0.62%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
DFTX-2.15%$45.15DYN+0.95%$26.50CRSP-0.02%$53.51MANE-3.47%$110.42EWTX+2.44%$44.58DNTH+2.64%$111.80CELC-2.14%$90.79TVTX-0.70%$60.89
Snapshot
Index-P/E12.98EPS (ttm)2.25Insider Own46.92%Shs Outstand171.24MPerf Week12.91%
Market Cap5.00BForward P/E31.70EPS next Y0.92Insider Trans-0.12%Shs Float169.05MPerf Month10.60%
Enterprise Value4.69BPEG0.19EPS next Q-Inst Own-Short Float6.52%Perf Quarter29.48%
Income379.64MP/S4.39EPS this Y-74.09%Inst Trans-Short Ratio6.50Perf Half Y24.51%
Sales1.14BP/B3.84EPS next Y61.61%ROA21.83%Short Interest11.03MPerf YTD9.36%
Book/sh-P/C25.80EPS next 5Y44.19%ROE32.39%52W High29.66 -0.92%Perf Year22.73%
Cash/sh-P/FCF28.68EPS past 3/5Y-ROIC6.19%52W Low19.81 48.35%Perf 3Y0.03%
Dividend Est.-EV/EBITDA40.40Sales past 3/5Y27.52% 19.39%Gross Margin91.13%Volatility4.42% 3.29%Perf 5Y35.04%
Dividend TTM-EV/Sales4.12EPS Y/Y TTM61.76%Oper. Margin7.59%ATR (14)0.98Perf 10Y-20.50%
Dividend Ex-Date-Quick Ratio3.30Sales Y/Y TTM14.41%Profit Margin33.42%RSI (14)73.20Recom2.32
Dividend Gr. 3/5Y-Current Ratio3.39EPS Q/Q-81.82%SMA2011.77%Beta0.86Target Price31.39
Payout0.00%Debt/Eq0.06Sales Q/Q9.84%SMA5020.19%Rel Volume1.09Prev Close29.21
Employees798LT Debt/Eq0.03EarningsNov 04SMA20022.69%Avg Volume1.63MPrice29.39
IPO DateMay 27, 2004Option/ShortYes / YesEPS/Sales Surpr.-60.40% -4.34%Net Debt/EBITDA-2.68Volume1,782,652Change0.62%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-05-26ReiteratedOppenheimerPerform$22 → $25
Aug-05-26ReiteratedRBC CapitalOutperform$36 → $37
Jul-29-26ReiteratedRaymond JamesOutperform$15
Jul-21-26ReiteratedBMO CapitalOutperform$31 → $36
Jul-07-26ReiteratedRBC CapitalOutperform$31 → $36
Jun-29-26ReiteratedDeutsche BankBuy$32 → $37
Jun-29-26ReiteratedCanaccord GenuityBuy$33 → $36
Mar-25-26UpgradeB of A SecuritiesNeutral → Buy
Mar-02-26ReiteratedWilliam Blair$29
Feb-23-26InitiatedWolfe ResearchOutperform$33
Latest News
Aug-07-26
Aug-07-2610:41AM
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?zacks.com
Aug-06-26
Aug-06-2601:21PM
Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?zacks.com
Aug-05-26
Aug-05-2608:12PM
3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectationszacks.com
01:50PM
Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 AdvancementSeekingAlpha
12:46PM
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Saleszacks.com
01:00AM
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-04-26
Aug-04-2606:41PM
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimateszacks.com
06:04PM
ACADIA Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
04:05PM
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Resultsbusinesswire.com
Aug-01-26
Aug-01-2603:50AM
Avidity Partners Management LP Sells 93,933 Shares of ACADIA Pharmaceuticals Inc. $ACADdefenseworld.net
Jul-30-26
Jul-30-2605:57PM
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conferencebusinesswire.com
12:41PM
HRMY or ACAD: Which Is the Better Value Stock Right Now?zacks.com
Jul-28-26
Jul-28-2611:06AM
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?zacks.com
Jul-27-26
Jul-27-2601:41PM
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?zacks.com
09:27AM
Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readoutseekingalpha.com
Company

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,1391,072958——————
Cost of Goods Sold Incl. D&A1018982——————
Gross Profit1,038983876——————
Selling, General and Administrative Excl. Other620549488——————
Research and Development332329303——————
Other Operating Expense-10-146——————
Operating Income86105231——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)363427——————
Net Income Before Taxes121139258——————
Income Taxes-259-25232——————
Consolidated Net Income382391226——————
Net Income From Continuing Operations382391226——————
Net Income382391226——————
EPS (Recurring)2.252.321.37——————
EPS (Basic, Before Extraordinaries)2.252.321.37——————
EPS (Diluted)2.222.291.36——————
EBITDA116151100——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio13.2411.6613.49——————
Price To Sales Ratio4.444.213.18——————
Gross Margin91.1391.7091.44——————
Operating Margin7.559.7924.11——————
Net Margin33.5436.4723.59——————
Shares Outstanding172169166——————
Market Capitalization5,0554,5143,046——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$30.58$27.61$24.63$21.66$18.69● Close Price0.00M0.25M0.51M0.76M1.01MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 06 '26Option Exercise17.8414,292254,96982,120Aug 07
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 06 '26Sale29.2214,292417,60467,828Aug 07
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 05 '26Option Exercise17.845,849104,34673,677Aug 07
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 05 '26Sale29.005,849169,63867,828Aug 07
Thompson Elizabeth H.Z.EVP, Head of Research & DevJul 30 '26Sale26.1316,558432,66318,994Jul 31
Thompson Elizabeth H.Z.EVP, Head of Research & DevJul 29 '26Option Exercise0.0032,272035,552Jul 31
Kihara JamesPRINCIPAL ACCOUNTING OFFICERJun 26 '26Sale26.0811,421297,91213,088Jun 29
GAROFALO ELIZABETH A.DirectorMay 29 '26Option Exercise0.008,107033,489Jun 01
Daly James MDirectorMay 29 '26Option Exercise0.008,107012,148Jun 01
HARRIGAN EDMUNDDirectorMay 29 '26Option Exercise0.008,107043,148Jun 01
Ndu AdoraDirectorMay 29 '26Option Exercise0.008,107032,908Jun 01
Brege LauraDirectorMay 29 '26Option Exercise0.008,107023,202Jun 01
Poole JonathanDirectorMay 29 '26Option Exercise0.002,01002,010Jun 01
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 26 '26Sale21.185,401114,39324,509May 27
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 04 '26Sale21.791,33229,02429,129May 05
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.